Despite having yet to save the life of a mouse, an Israeli company is making grandiose pronouncements. However, if you look beyond the hype the medical approach is actually pretty interesting.
John LaMattina, the former head of R&D at Pfizer, tackles a timely and important topic in his Forbes piece today: What is the best way to do oncology research? And, can it save money as well as lives?
Modern clinical research has turned to harnessing a patient s own immune system to block the proliferation of cancer cells. The
By far, the major thrust of pharmaceutical research at this time is aimed at cancer. In 2102, a record eleven oncology drugs were approved by the FDA. Unfortunately, most advances have been incremental, and cures for most previously incurable cancers remain elusive.